Cytosorbents : Q2 2023 Press Release -Today at 04:45 am : vi

CytoSorbents Reports Second Quarter 2023 Financial and Operational


Results


Q2 2023 Total Revenue was $9.4 million, an 11% increase from $8.5...

Related Keywords

Canada , Canadian , Humedic Limax , Michael Bator , Eli Lilly , Kathy Bloch , Phillip Chan , Daiichi Sankyo , Al Krausas , Health Canada , Healthcare Research At Jennison Associates , Partner Of Quartz Advisory Group , Cytosorbents Corporation , Astrazeneca , Cytosorbents Reports Second Quarter , Sorbents Corporation , Operating Highlights , Safety Monitoring Board , Alexanderd Amico , Chief Financial Officer , Annual Meeting , Quartz Advisory Group , Managing Director , Healthcare Research , Jennison Associates , Chief Executive Officer , Timely Antithromobotic Removal , Principal Investigators , Although Brilinta , Clinical Treatment Dynamics , Percutaneous Coronary Intervention , Timely Antithrombotic Removal , Transitional Coverage , Emerging Technologies , Designated Devices , Breakthrough Devices , Breakthrough Designated Device , Sales Growth , Critical Care , Right Timing , Right Dose , Cytosorb Therapy , Markets ,